Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.

Lacombe P, Deschênes D, Dubé D, Dubé L, Gallant M, Macdonald D, Mastracchio A, Perrier H, Charleson S, Huang Z, Laliberté F, Liu S, Mancini JA, Masson P, Salem M, Styhler A, Girard Y.

Bioorg Med Chem Lett. 2006 May 15;16(10):2608-12. Epub 2006 Mar 3.

PMID:
16516471
2.

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Macdonald D, Mastracchio A, Perrier H, Dubé D, Gallant M, Lacombe P, Deschênes D, Roy B, Scheigetz J, Bateman K, Li C, Trimble LA, Day S, Chauret N, Nicoll-Griffith DA, Silva JM, Huang Z, Laliberté F, Liu S, Ethier D, Pon D, Muise E, Boulet L, Chan CC, Styhler A, Charleson S, Mancini J, Masson P, Claveau D, Nicholson D, Turner M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6. Epub 2005 Sep 15.

PMID:
16168647
3.

3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.

Black WC, Brideau C, Chan CC, Charleson S, Cromlish W, Gordon R, Grimm EL, Hughes G, Leger S, Li CS, Riendeau D, Thérien M, Wang Z, Xu LJ, Prasit P.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1195-8.

PMID:
12643942
4.

Pyridazinones as selective cyclooxygenase-2 inhibitors.

Li CS, Brideau C, Chan CC, Savoie C, Claveau D, Charleson S, Gordon R, Greig G, Gauthier JY, Lau CK, Riendeau D, Thérien M, Wong E, Prasit P.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):597-600.

PMID:
12639538
5.

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC.

J Pharmacol Exp Ther. 2001 Feb;296(2):558-66.

PMID:
11160644
6.

Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors.

Lau CK, Brideau C, Chan CC, Charleson S, Cromlish WA, Ethier D, Gauthier JY, Gordon R, Guay J, Kargman S, Li CS, Prasit P, Riendeau D, Thérien M, Visco DM, Xu L.

Bioorg Med Chem Lett. 1999 Nov 15;9(22):3187-92.

PMID:
10576685
7.

A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.

Li CS, Black WC, Brideau C, Chan CC, Charleson S, Cromlish WA, Claveau D, Gauthier JY, Gordon R, Greig G, Grimm E, Guay J, Lau CK, Riendeau D, Thérien M, Visco DM, Wong E, Xu L, Prasit P.

Bioorg Med Chem Lett. 1999 Nov 15;9(22):3181-6.

PMID:
10576684
8.

Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.

Frenette R, Hutchinson JH, Léger S, Thérien M, Brideau C, Chan CC, Charleson S, Ethier D, Guay J, Jones TR, McAuliffe M, Piechuta H, Riendeau D, Tagari P, Girard Y.

Bioorg Med Chem Lett. 1999 Aug 16;9(16):2391-6.

PMID:
10476875
9.

SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor.

Leblanc Y, Roy P, Boyce S, Brideau C, Chan CC, Charleson S, Gordon R, Grimm E, Guay J, Léger S, Li CS, Riendeau D, Visco D, Wang Z, Webb J, Xu LJ, Prasit P.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2207-12.

PMID:
10465547
10.

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al.

J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.

PMID:
10411562
11.

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8.

PMID:
10406640
12.

2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.

Black WC, Brideau C, Chan CC, Charleson S, Chauret N, Claveau D, Ethier D, Gordon R, Greig G, Guay J, Hughes G, Jolicoeur P, Leblanc Y, Nicoll-Griffith D, Ouimet N, Riendeau D, Visco D, Wang Z, Xu L, Prasit P.

J Med Chem. 1999 Apr 8;42(7):1274-81.

PMID:
10197970
13.

Substituted heterocyclic analogs as selective COX-2 inhibitors in the flosulide class.

Ouimet N, Chan CC, Charleson S, Claveau D, Gordon R, Guay D, Li CS, Ouellet M, Percival DM, Riendeau D, Wong E, Zamboni R, Prasit P.

Bioorg Med Chem Lett. 1999 Jan 18;9(2):151-6.

PMID:
10021918
14.

2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.

Friesen RW, Brideau C, Chan CC, Charleson S, Deschênes D, Dubé D, Ethier D, Fortin R, Gauthier JY, Girard Y, Gordon R, Greig GM, Riendeau D, Savoie C, Wang Z, Wong E, Visco D, Xu LJ, Young RN.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2777-82.

PMID:
9873621
15.
16.

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.

Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC, et al.

Br J Pharmacol. 1997 May;121(1):105-17.

17.

Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells.

Wong E, DeLuca C, Boily C, Charleson S, Cromlish W, Denis D, Kargman S, Kennedy BP, Ouellet M, Skorey K, O'Neill GP, Vickers PJ, Riendeau D.

Inflamm Res. 1997 Feb;46(2):51-9.

PMID:
9085144
18.

From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors.

Lau CK, Black WC, Belley M, Chan C, Charleson S, Denis D, Gauthier JY, Gordon R, Guay D, Hamel P, Kargman S, Leblanc Y, Mancini J, Ouellet M, Percival D, Prasit P, Roy P, Skorey K, Tagari P, Vickers P, Wong E.

Adv Exp Med Biol. 1997;407:73-8. No abstract available.

PMID:
9321934
19.

Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts.

Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, Evans J, O'Neill G.

Gastroenterology. 1996 Aug;111(2):445-54.

PMID:
8690211
20.

Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.

Hutchinson JH, Charleson S, Evans JF, Falgueyret JP, Hoogsteen K, Jones TR, Kargman S, Macdonald D, McFarlane CS, Nicholson DW, et al.

J Med Chem. 1995 Oct 27;38(22):4538-47.

PMID:
7473582
21.

Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein.

Charleson S, Evans JF, Léger S, Perrier H, Prasit P, Wang Z, Vickers PJ.

Eur J Pharmacol. 1994 May 17;267(3):275-80.

PMID:
8088366
22.

The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein.

Mancini JA, Coppolino MG, Klassen JH, Charleson S, Vickers PJ.

Life Sci. 1994;54(9):PL137-42.

PMID:
8114608
23.

5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.

Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, Heibein JA, Charleson S, Singer II.

J Exp Med. 1993 Dec 1;178(6):1935-46.

24.

5-lipoxygenase-activating protein is an arachidonate binding protein.

Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, Wang Z, Prasit P, Vickers PJ.

FEBS Lett. 1993 Mar 8;318(3):277-81.

25.

Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors.

Vickers PJ, Adam M, Charleson S, Abramovitz M, O'Neill G, Mancini JA.

J Lipid Mediat. 1993 Mar-Apr;6(1-3):31-42.

PMID:
8357989
26.

A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.

Prasit P, Belley M, Blouin M, Brideau C, Chan C, Charleson S, Evans JF, Frenette R, Gauthier JY, Guay J, et al.

J Lipid Mediat. 1993 Mar-Apr;6(1-3):239-44.

PMID:
8357985
27.

Cross-species comparison of 5-lipoxygenase-activating protein.

Vickers PJ, O'Neill GP, Mancini JA, Charleson S, Abramovitz M.

Mol Pharmacol. 1992 Dec;42(6):1014-9.

PMID:
1480129
28.

Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors.

Vickers PJ, Adam M, Charleson S, Coppolino MG, Evans JF, Mancini JA.

Mol Pharmacol. 1992 Jul;42(1):94-102.

PMID:
1635556
29.

Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.

Brideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, Fortin R, Gillard JW, Guay J, Guévremont D, et al.

Can J Physiol Pharmacol. 1992 Jun;70(6):799-807.

PMID:
1330258
30.

Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.

Charleson S, Prasit P, Léger S, Gillard JW, Vickers PJ, Mancini JA, Charleson P, Guay J, Ford-Hutchinson AW, Evans JF.

Mol Pharmacol. 1992 May;41(5):873-9.

PMID:
1588922
31.

Urinary leukotriene E4 levels during early and late asthmatic responses.

Manning PJ, Rokach J, Malo JL, Ethier D, Cartier A, Girard Y, Charleson S, O'Byrne PM.

J Allergy Clin Immunol. 1990 Aug;86(2):211-20.

PMID:
2166758
32.

BIO-Fully Automated Sample Treatment high-performance liquid chromatography and radioimmunoassay for leukotriene E4 in human urine from asthmatics.

Nicoll-Griffith D, Zamboni R, Rasmussen JB, Ethier D, Charleson S, Tagari P.

J Chromatogr. 1990 Apr 6;526(2):341-54.

PMID:
2163406
33.

Increased leukotriene E4 excretion during antigen-induced bronchoconstriction in allergic sheep.

Tagari P, Abraham WM, McGolrick J, Charleson S, Soler M, Ahmed A, Cortez A, Ford-Hutchinson AW.

J Appl Physiol (1985). 1990 Apr;68(4):1321-7.

PMID:
2161409
34.

Comparison of urinary leukotriene E4 and 16-carboxytetranordihydro leukotriene E4 excretion in allergic asthmatics after inhaled antigen.

Tagari P, Rasmussen JB, Delorme D, Girard Y, Eriksson LO, Charleson S, Ford-Hutchinson AW.

Eicosanoids. 1990;3(2):75-80.

PMID:
2169776
35.

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.

Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, Fortin R, Leger S, McFarlane CS, Morton H, et al.

Can J Physiol Pharmacol. 1989 May;67(5):456-64.

PMID:
2548691
36.

Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radioimmunoassay.

Tagari P, Ethier D, Carry M, Korley V, Charleson S, Girard Y, Zamboni R.

Clin Chem. 1989 Mar;35(3):388-91.

37.

The in vivo production of peptide leukotrienes after pulmonary anaphylaxis in the rat.

Foster A, Letts G, Charleson S, Fitzsimmons B, Blacklock B, Rokach J.

J Immunol. 1988 Nov 15;141(10):3544-50.

PMID:
2846689
38.

Leukotriene B4 receptors on rat and human neutrophil membranes.

Ford-Hutchinson AW, Charleson S, Evans JF.

Methods Enzymol. 1988;163:340-3. No abstract available.

PMID:
2853282
39.

5-Lipoxygenase inhibitors and allergic conjunctivitis reactions in the guinea-pig.

Garceau D, Ford-Hutchinson AW, Charleson S.

Eur J Pharmacol. 1987 Nov 3;143(1):1-7.

PMID:
2826183
40.

Analogs of leukotriene B4: effects of modification of the hydroxyl groups on leukocyte aggregation and binding to leukocyte leukotriene B4 receptors.

Leblanc Y, Fitzsimmons BJ, Charleson S, Alexander P, Evans JF, Rokach J.

Prostaglandins. 1987 May;33(5):617-25.

PMID:
3035618
41.

Activation of leukocyte movement and displacement of [3H]leukotriene B4 from leukocyte membrane preparations by (12R)- and (12S)-hydroxyeicosatetraenoic acid.

Evans JF, Leblanc Y, Fitzsimmons BJ, Charleson S, Nathaniel D, Léveillé C.

Biochim Biophys Acta. 1987 Feb 23;917(3):406-10.

PMID:
3026490
42.

Leukotriene B3, leukotriene B4 and leukotriene B5; binding to leukotriene B4 receptors on rat and human leukocyte membranes.

Charleson S, Evans JF, Zamboni RJ, Leblanc Y, Fitzsimmons BJ, Leveillé C, Dupuis P, Ford-Hutchinson AW.

Prostaglandins. 1986 Oct;32(4):503-16.

PMID:
3025936
43.

Neutrophil LTA4 hydrolases and leukotriene B4 receptors: effects of leukotriene epoxides and their enzymatic products.

Evans J, Nathaniel D, Charleson S, Léveillé C, Zamboni R, Leblanc Y, Frenette R, Fitzsimmons BJ, Leger S, Hamel P, et al.

Prostaglandins Leukot Med. 1986 Aug;23(2-3):167-71.

PMID:
3020583
44.

Production of leukotrienes in human skin and conjunctival mucosa after specific allergen challenge.

Bisgaard H, Ford-Hutchinson AW, Charleson S, Taudorf E.

Allergy. 1985 Aug;40(6):417-23.

PMID:
2996379
45.

Antigen-induced leukotriene release from rat lung in vitro.

Brunet G, Charleson S, Ford-Hutchinson AW.

Prostaglandins. 1985 Jun;29(6):921-32.

PMID:
4034992
46.

Leukotriene F4 and the release of arachidonic acid metabolites from perfused guinea pig lungs in vitro.

Lord A, Charleson S, Letts LG.

Prostaglandins. 1985 Apr;29(4):651-60.

PMID:
3923570
47.

Leukotrienes C4 and D4 in psoriatic skin lesions.

Brain SD, Camp RD, Black AK, Dowd PM, Greaves MW, Ford-Hutchinson AW, Charleson S.

Prostaglandins. 1985 Apr;29(4):611-9.

PMID:
2988023
48.

Leukotriene B4, polymorphonuclear leukocytes and inflammatory exudates in the rat.

Ford-Hutchinson AW, Brunet G, Savard P, Charleson S.

Prostaglandins. 1984 Jul;28(1):13-27.

PMID:
6091186
49.

Detection of leukotriene C4-liked immunoreactivity in tear fluid from subjects challenged with specific allergen.

Bisgaard H, Ford-Hutchinson AW, Charleson S, Taudorf E.

Prostaglandins. 1984 Mar;27(3):369-74.

PMID:
6729144
50.

Synthesis and biological activities of leukotriene F4 and leukotriene F4 sulfone.

Denis D, Charleson S, Rackham A, Jones TR, Ford-Hutchinson AW, Lord A, Cirino M, Girard Y, Larue M, Rokach J.

Prostaglandins. 1982 Dec;24(6):801-14.

PMID:
6300970

Supplemental Content

Loading ...
Support Center